Photobiomodulation effect on local hemoglobin concentration assessed by near-infrared spectroscopy in humans

Effects of Short-, Medium-, and Long-Term Treatment Using Photobiomodulation Therapy Combined with Static Magnetic Field in Aging Rats

(1) Background: We investigated the detrimental and protective effects of short-, medium, and long-term treatment with different doses of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) during the aging process. (2) Methods: Rats were treated for 15, 30, and 60 weeks with 1, 3, 10, and 30 J of PBMT-sMF or a placebo control. In addition, eight young rats were not subjected to any procedure or treatment and were euthanized at six weeks old. Skin, muscle, bone, kidney, liver, and blood samples were analyzed. (3) Results: No differences between the groups in the morphology of the skin, muscle, and bone was observed. Glutamic pyruvic transaminase levels were increased in the placebo group after 30 and 60 weeks. Glutamic oxaloacetic transaminase levels were also increased in the placebo group after 30 weeks. An increase in creatinine in the PBMT-sMF 3, 10, and 30 J groups compared with that in the young control group was observed. No significant difference in urea levels between the groups was noted. Vascular endothelial growth factor increased in the PBMT-sMF 10 and 30 J groups after 15 weeks of treatment and in the PBMT-sMF 3 J after 60 weeks. Finally, vascular endothelial growth factor decreased in the PBMT-sMF 30 J group after 30 weeks of treatment. (4) Conclusions: PBMT-sMF did not have detrimental effects on the skin, muscle, bone, kidney, or liver after short-, medium-, and long-term treatments in aging rats. In addition, PBMT-sMF may have protective effects on the muscle tissue in aging rats after short- and long-term treatment.

Innovative integration: optimizing performance through warm-up and photobiomodulation in high-intensity test

We investigated whether the application of photobiomodulation therapy (PBMT) immediately after a standardized warm-up (WU + PBMT) or traditional PBMT (no pre-warming) would influence performance in intermittent testing and intensity variables. In a counterbalanced randomized crossover design, twelve female futsal players (mean age: 23.9 ± 3.8 years) attended four sessions. Each session involved either a standardized warm-up or maintaining seated rest for five minutes. Subsequently, PBMT or placebo (with the PBMT device turned off) was applied, followed by the YoYo Intermittent Recovery Level 1 test (YYIR1) during which we assessed heart rate, rating of perceived exertion, and blood lactate levels. The performance in YYIIR1 was superior (p = 0.02) in the WU + PBMT condition (440.0 ± 59.0 m) compared to the WU + Placebo (353.3 ± 94.7 m), and placebo alone (no warm-up) (325.0 ± 67.2 m). We conclude that a combination of a specific warm-up before PBMT application improves high-intensity intermittent performance in amateur female futsal players without affecting intensity variables.

Effects of photobiomodulation as an adjunctive treatment in chronic obstructive pulmonary disease: a narrative review

Chronic obstructive pulmonary disease (COPD) is a disease characterized by chronic airway inflammation and remodeling and lung parenchymal inflammation and destruction, which result in many pulmonary and extrapulmonary manifestations. The anti-inflammatory effect of photobiomodulation (PBM) has been reported in previous studies. This review was conducted to evaluate the direct effect of PBM on lung inflammation in COPD. The other effects of PBM on modulation of peripheral and respiratory muscle metabolism and angiogenesis in lung tissues were also discussed. The databases of PubMed, Cochrane Library, and Google Scholar were searched to find the relevant studies. Keywords included PBM and related terms, COPD-related signs, and lung inflammation. A total of 12 articles were selected and reviewed in this study. Based on the present review, PBM is helpful in reducing lung inflammation through decreasing the inflammatory cytokines and chemokines at multiple levels and increasing anti-inflammatory cytokines. In addition, PBM also improves both peripheral and respiratory muscle metabolism and promote angiogenesis. This review demonstrated that PBM is a promising adjunctive treatment modality for COPD management which merits further validation.

A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 virus was first recognized in late 2019 and remains a significant threat. We therefore assessed the use of local methylene blue photodynamic viral inactivation (MB-PDI) in the oral and nasal cavities, in combination with the systemic anti-viral, anti-inflammatory and antioxidant actions of orally ingested methylene blue (MB) and photobiomodulation (PBM) for COVID-19 disease. The proposed protocol leverages the separate and combined effects of MB and 660nm red light emitted diode (LED) to comprehensively address the pathophysiological sequelae of COVID-19. A total of eight pilot subjects with COVID-19 disease were treated in the Bahamas over the period June 2021-August 2021, using a remote care program that was developed for this purpose. Although not a pre-requisite for inclusion, none of the subjects had received any COVID-19 vaccination prior to commencing the study. Clinical outcome assessment tools included serial cycle threshold measurements as a surrogate estimate of viral load; serial online questionnaires to document symptom response and adverse effects; and a one-year follow-up survey to assess long-term outcomes. All subjects received MB-PDI to target the main sites of viral entry in the nose and mouth. This was the central component of the treatment protocol with the addition of orally ingested MB and/or PBM based on clinical requirements. The mucosal surfaces were irradiated with 660 nm LED in a continuous emission mode at energy density of 49 J/cm2 for PDI and 4.9 J/cm2 for PBM. Although our pilot subjects had significant co-morbidities, extremely high viral loads and moderately severe symptoms during the Delta phase of the pandemic, the response to treatment was highly encouraging. Rapid reductions in viral loads were observed and negative PCR tests were documented within a median of 4 days. These laboratory findings occurred in parallel with significant clinical improvement, mostly within 12-24 h of commencing the treatment protocol. There were no significant adverse effects and none of the subjects who completed the protocol required in-patient hospitalization. The outcomes were similarly encouraging at one-year follow-up with virtual absence of "long COVID" symptoms or of COVID-19 re-infection. Our results indicate that the protocols may be a safe and promising approach to challenging COVID-19 disease. Moreover, due its broad spectrum of activity, this approach has the potential to address the prevailing and future COVID-19 variants and other infections transmitted via the upper respiratory tract. Extensive studies with a large cohort are warranted to validate our results.

Deconstructing the Ergogenic Effects of Photobiomodulation: A Systematic Review and Meta-analysis of its Efficacy in Improving Mode-Specific Exercise Performance in Humans

BACKGROUND

Photobiomodulation therapy (PBMT) is defined as non-thermal electromagnetic irradiation through laser or light-emitting diode sources. In recent decades, PBMT has attracted attention as a potential preconditioning method. The current meta-analysis was conducted to assess the effectiveness of PBMT in improving mode-specific exercise performance in healthy young adults.

METHODS

A computerized literature search was conducted, ending on 15 May 2022. The databases searched were PubMed, Cochrane Central Register of Controlled Trials, Embase, SPORTDiscus, and the Physiotherapy Evidence Database. Inclusion/exclusion criteria limited articles to crossover, double-blind, placebo-controlled studies investigating the PBMT effects as a preconditioning method. The included trials were synthesized according to exercise mode (single-joint, cycling, running, and swimming). All results were combined using the standardized mean differences (SMDs) method and the 95% confidence intervals (CIs) were described.

RESULTS

A total of 37 individual studies, employing 78 exercise performance measurements in 586 participants, were included in the analyses. In single-joint exercises, PBMT improved muscle endurance performance (SMD 0.27, 95% CI 0.12-0.41; p < 0.01) but not muscle strength performance (p = 0.92). In cycling, PBMT improved time to exhaustion performance (SMD 0.35, 95% CI 0.10-0.59; p < 0.01) but had no effect on all-out sprint performance (p = 0.96). Similarly, PBMT had no effect on time to exhaustion (p = 0.10), time-trial (p = 0.61), or repeated-sprint (p = 0.37) performance in running and no effect on time-trial performance in swimming (p = 0.81).

CONCLUSION

PBMT improves muscle endurance performance in single-joint exercises and time to exhaustion performance in cycling but is not effective for muscle strength performance in single-joint exercises, running, or swimming performance metrics.

Dose Response Effect of Photobiomodulation on Hemodynamic Responses and Glucose Levels in Men with Type 2 Diabetes: A Randomized, Crossover, Double-Blind, Sham-Controlled Trial

This study verifies the acute dose response effect of photobiomodulation (PBM) by light emitting diodes (LEDs) on hemodynamic and metabolic responses in individuals with type 2 diabetes mellitus (T2DM). Thirteen participants with T2DM (age 52 ± 7 years) received PBM by a light-emitting diode array (50 GaAIAs LEDs, 850 ± 20 nm, 75 mW per diode) on the rectus and oblique abdomen, quadriceps femoris, triceps surae, and hamstring muscle areas, bilaterally, using different energy treatments (sham, 75, 150, 300, 450, and 600 Joules) in random order with a washout of at least 15 days apart. The PBM by LEDs statistically decreased plasma glucose levels (primary outcome) in 15 min after application of the 75 and 450 J irradiation protocol, reduced blood lactate levels 15 min after application of the 75, 450, and 600 J irradiation protocol, increased cardiac output (Q˙) and cardiac index (CI) in the 1st minute after application of the 75 and 300 J irradiation protocol, and reduced Q˙ and heart rate (HR) in the 15 min after application of the 300 J and 600 J irradiation protocol, respectively. For hemodynamic variables, including Q˙, total peripheral resistance (TPR), and HR, we observed that the ideal therapeutic window ranged between 75 and 300 J, while for metabolic variables, glucose and lactate, the variation was between 450 and 600 J.

New evidence from hyperspectral imaging analysis on the effect of photobiomodulation therapy on normal skin oxygenation

The aim of this study was to assess the changes induced by photobiomodulation therapy in oxygenation of normal skin and underlying tissue using hyperspectral imaging combined with a chemometric regression approach. Eleven healthy adult volunteers were enrolled in this study. The dorsal side of the left hand of each subject was exposed to photobiomodulation therapy, while the correspondent side of the right hand was used as a control (placebo effect). Laser irradiation was performed with a laser diode system (635 nm, 15mW, 9 J/cm²) for 900 s. Changes in skin oxygenation were assessed before and after applying the photobiomodulation therapy and placebo using the hyperspectral imaging. Hyperspectral data analysis showed that variations of oxyhemoglobin and deoxyhemoglobin concentrations had no statistical significance in both groups. In conclusion, photobiomodulation therapy does not induce changes in oxyhemoglobin and deoxyhemoglobin concentrations in the normal skin measured from hyperspectral images, at least at λ = 635 nm and 900-s exposure time.

Effects of Photobiomodulation Therapy Combined with Static Magnetic Field in Severe COVID-19 Patients Requiring Intubation: A Pragmatic Randomized Placebo-Controlled Trial

Purpose

We aimed to investigate the effects of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) on the length of intensive care unit (ICU) stay and mortality rate of severe COVID-19 patients requiring invasive mechanical ventilation and assess its role in preserving respiratory muscles and modulating inflammatory processes.

Patients and Methods

We conducted a prospectively registered, triple-blinded, randomized, placebo-controlled trial of PBMT-sMF in severe COVID-19 ICU patients requiring invasive mechanical ventilation. Patients were randomly assigned to receive either PBMT-sMF or a placebo daily throughout their ICU stay. The primary outcome was length of ICU stay, defined by either discharge or death. The secondary outcomes were survival rate, diaphragm muscle function, and the changes in blood parameters, ventilatory parameters, and arterial blood gases.

Results

Thirty patients were included and equally randomized into the two groups. There were no significant differences in the length of ICU stay (mean difference, MD = −6.80; 95% CI = −18.71 to 5.11) between the groups. Among the secondary outcomes, significant differences were observed in diaphragm thickness, fraction of inspired oxygen, partial pressure of oxygen/fraction of inspired oxygen ratio, C-reactive protein levels, lymphocyte count, and hemoglobin (p < 0.05).

Conclusion

Among severe COVID-19 patients requiring invasive mechanical ventilation, the length of ICU stay was not significantly different between the PBMT-sMF and placebo groups. In contrast, PBMT-sMF was significantly associated with reduced diaphragm atrophy, improved ventilatory parameters and lymphocyte count, and decreased C-reactive protein levels and hemoglobin count.

Trial Registration Number (Clinical Trials.gov)

NCT04386694.

Effects of Photobiomodulation Therapy Combined with Static Magnetic Field in Severe COVID-19 Patients Requiring Intubation: A Pragmatic Randomized Placebo-Controlled Trial

PURPOSE

We aimed to investigate the effects of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) on the length of intensive care unit (ICU) stay and mortality rate of severe COVID-19 patients requiring invasive mechanical ventilation and assess its role in preserving respiratory muscles and modulating inflammatory processes.

PATIENTS AND METHODS

We conducted a prospectively registered, triple-blinded, randomized, placebo-controlled trial of PBMT-sMF in severe COVID-19 ICU patients requiring invasive mechanical ventilation. Patients were randomly assigned to receive either PBMT-sMF or a placebo daily throughout their ICU stay. The primary outcome was length of ICU stay, defined by either discharge or death. The secondary outcomes were survival rate, diaphragm muscle function, and the changes in blood parameters, ventilatory parameters, and arterial blood gases.

RESULTS

Thirty patients were included and equally randomized into the two groups. There were no significant differences in the length of ICU stay (mean difference, MD = -6.80; 95% CI = -18.71 to 5.11) between the groups. Among the secondary outcomes, significant differences were observed in diaphragm thickness, fraction of inspired oxygen, partial pressure of oxygen/fraction of inspired oxygen ratio, C-reactive protein levels, lymphocyte count, and hemoglobin (p < 0.05).

CONCLUSION

Among severe COVID-19 patients requiring invasive mechanical ventilation, the length of ICU stay was not significantly different between the PBMT-sMF and placebo groups. In contrast, PBMT-sMF was significantly associated with reduced diaphragm atrophy, improved ventilatory parameters and lymphocyte count, and decreased C-reactive protein levels and hemoglobin count.

TRIAL REGISTRATION NUMBER CLINICAL TRIALSGOV

NCT04386694.

Acute Photobiomodulation by LED Does Not Alter Muscle Fatigue and Cycling Performance

PURPOSE

The purpose of the present study was to investigate the ergogenic effects of two doses of photobiomodulation therapy (PBMT) in comparison to placebo on markers of respiratory and muscle activity, blood acid-base, ion and lactate concentrations, indicators of muscle fatigue (global, central, and peripheral), and time to exhaustion in severe-intensity cycling.

METHODS

Two separate studies were performed, both in a pseudorandomized and balanced, crossover design. In study 1, 14 male recreational cyclists completed three constant-load, severe-intensity cycling bouts that were duration matched. The PBMT (18 × 38 cm array with 200 diodes) treatments occurred before bouts at 260, 130, or 0 J (placebo) doses. EMG activity of selected lower limb musculature was assessed during each bout. Maximal voluntary contractions of knee extension with peripheral nerve stimulations and EMG activity evaluation of vastus lateralis was also performed before and after cycling. In study 2, 13 recreational cyclists performed three bouts of constant-load, severe-intensity cycling until exhaustion, preceded by PBMT as detailed previously. Blood lactate concentrations, respiratory responses, EMG activity, and capillary gasometry aspects were monitored.

RESULTS

In both studies, there were no interactions effects (time-condition) on the EMG activity, which was displayed as root mean square (P ≥ 0.168) and median frequency (P ≥ 0.055) during cycling. In study 1, there were no interaction effects on the indicators of muscle fatigue after exercise (P ≥ 0.130). In study 2, there were no differences on time to exhaustion (P = 0.353) and no interaction effects among the physiological responses monitored (P ≥ 0.082).

CONCLUSIONS

Based on our findings, the PBMT at 260- and 130-J doses does not have a beneficial effect on muscle fatigue, cycling performance, metabolic parameters, and muscle activity in male recreational cyclists.

Photobiomodulation 30 min or 6 h Prior to Cycling Does Not Alter Resting Blood Flow Velocity, Exercise-Induced Physiological Responses or Time to Exhaustion in Healthy Men

Purpose

The aim of the current study was to investigate the effects of photobiomodulation therapy (PBMT) applied 30 min or 6 h prior to cycling on blood flow velocity and plasma nitrite concentrations at rest, time to exhaustion, cardiorespiratory responses, blood acid-base balance, and K⁺ and lactate concentrations during exercise.

Methods

In a randomized, crossover design, 13 healthy untrained men randomly completed four cycling bouts until exhaustion at the severe-intensity domain (i.e., above respiratory compensation point). Thirty minutes or 6 h prior to the cycling trials, participants were treated with PBMT on the quadriceps, hamstrings, and gastrocnemius muscles of both limbs using a multi-diode array (11 cm × 30 cm with 264 diodes) at doses of 152 J or a sham irradiation (with device turned off, placebo). Blood samples were collected before and 30 min or 6 h after treatments to measure plasmatic nitrite concentrations. Doppler ultrasound exams of the femoral artery were also performed at the same time points. Cardiorespiratory responses, blood acid-base balance, and K⁺ and lactate concentrations were monitored during exercise sessions.

Results

PBMT did not improve the time to exhaustion (p = 0.30). At rest, no differences were found in the peak systolic velocity (p = 0.97) or pulsatility index (p = 0.83) in the femoral artery, and in plasma nitrite concentrations (p = 0.47). During exercise, there were no differences for any cardiorespiratory response monitored (heart rate, p = 0.15; oxygen uptake, p = 0.15; pulmonary ventilation, p = 0.67; carbon dioxide output, p = 0.93; and respiratory exchange ratio, p = 0.32), any blood acid-base balance indicator (pH, p = 0.74; base excess, p = 0.33; bicarbonate concentration, p = 0.54), or K⁺ (p = 0.22) and lactate (p = 0.55) concentrations.

Conclusions

PBMT at 152 J applied 30 min or 6 h before cycling at severe-intensity did not alter resting plasma nitrite and blood flow velocity in the femoral artery, exercise-induced physiological responses, or time to exhaustion in healthy untrained men.

Phototherapy as a Rational Antioxidant Treatment Modality in COVID-19 Management; New Concept and Strategic Approach: Critical Review

The COVID-19 pandemic has taken the entire globe by storm. The pathogenesis of this virus has shown a cytokine storm release, which contributes to critical or severe multi-organ failure. Currently the ultimate treatment is palliative; however, many modalities have been introduced with effective or minimal outcomes. Meanwhile, enormous efforts are ongoing to produce safe vaccines and therapies. Phototherapy has a wide range of clinical applications against various maladies. This necessitates the exploration of the role of phototherapy, if any, for COVID-19. This critical review was conducted to understand COVID-19 disease and highlights the prevailing facts that link phototherapy utilisation as a potential treatment modality for SARS-CoV-2 viral infection. The results demonstrated phototherapy's efficacy in regulating cytokines and inflammatory mediators, increasing angiogenesis and enhancing healing in chronic pulmonary inflammatory diseases. In conclusion, this review answered the following research question. Which molecular and cellular mechanisms of action of phototherapy have demonstrated great potential in enhancing the immune response and reducing host-viral interaction in COVID-19 patients? Therefore, phototherapy is a promising treatment modality, which needs to be validated further for COVID-19 by robust and rigorous randomised, double blind, placebo-controlled, clinical trials to evaluate its impartial outcomes and safety.

Does photobiomodulation therapy combined to static magnetic field (PBMT-sMF) promote ergogenic effects even when the exercised muscle group is not irradiated? A randomized, triple-blind, placebo-controlled trial

Background

The direct application of photobiomodulation therapy (PBMT) using low-level laser therapy (LLLT) and light emitting diodes (LEDs) combined with a static magnetic field (sMF) (PBMT-sMF) to target tissues is shown to improve muscle performance and recovery. Studies have reported possible PBMT effects when a local distant to the target tissue is irradiated. Notably, the extent of these effects on musculoskeletal performance and the optimal site of irradiation remain unclear, although this information is clinically important since these aspects could directly affect the magnitude of the effect. Therefore, we investigated the effects of local and non-local PBMT-sMF irradiations on musculoskeletal performance and post-exercise recovery before an eccentric exercise protocol.

Methods

This randomized, triple-blind (participants, therapists and assessors), placebo-controlled trial included 30 healthy male volunteers randomly assigned to the placebo, local, and non-local groups. Active or placebo PBMT-sMF was applied to 6 sites of the quadriceps muscle of both legs. An eccentric exercise protocol was used to induce fatigue. The primary outcome was peak torque assessed by maximal voluntary contraction (MVC). The secondary outcomes were delayed onset muscle soreness (DOMS) measured by visual analogue scale (VAS), muscle injury assessed by serum creatine kinase activity (CK), and blood lactate levels. Evaluations were performed before the eccentric exercise protocol (baseline), as well as immediately after and 1, 24, 48, and 72 h upon protocol completion.

Results

Ten volunteers were randomized per group and analysed for all outcomes. Compared to the placebo and non-local groups, irradiation with PBMT-SMF led to statistically significant improvement (p < 0.05) with regard to all variables in the local group. The outcomes observed in the non-local group were similar to those in the placebo group with regard to all variables.The volunteers did not report any adverse effects.

Conclusion

Our results support the current evidence that local irradiation of all exercised muscles promotes ergogenic effects. PBMT-sMF improved performance and reduced muscle fatigue only when applied locally to muscles involved in physical activity.

Trial registration

NCT03695458. Registered October 04th 2018.

Acute effects of photobiomodulation therapy applied to respiratory muscles of chronic obstructive pulmonary disease patients: a double-blind, randomized, placebo-controlled crossover trial

To investigate the effects of photobiomodulation applied to respiratory muscles on lung function, thoracoabdominal mobility, respiratory muscle strength, and functional capacity in COPD patients. This is a randomized double-blind crossover clinical trial. Twelve male COPD patients participated in the study. Participants were randomly allocated to receive two photobiomodulation sessions, 1 week apart: (1) an effective photobiomodulation session applied at the main respiratory muscles by means of a cluster with 69 light-emitting diodes (LEDs), containing 35 red (630 ± 10 nm; 10 mW; 0.2 cm²) and 34 near-infrared (830 ± 20 nm; 10 mW; 0.2 cm²) LEDs and (2) a sham photobiomodulation session, following the same procedures without emitting light. The primary outcomes were pulmonary function (spirometric indexes); thoracoabdominal mobility (cirtometry); respiratory muscle strength (maximal respiratory pressures), assessed at three moments: (1) baseline, (2) 1 h after intervention, and (3) 24 h after intervention; and the functional capacity, assessed by the 6-min walk test (6MWT) at baseline and 24 h after intervention. No significant interactions were found for spirometric variables, maximal respiratory pressures, and cirtometry. However, there was a Time × Condition interaction (F = 18.63; p = 0.001; η²_p = 0.62) in the walked distance on the 6MWT, with a significant increase after photobiomodulation intervention (p < 0.01) compared with the baseline. Photobiomodulation applied to respiratory muscles was effective in improving acute functional capacity in COPD patients. To the best of our knowledge, this is the first study assessing the effects of photobiomodulation applied to respiratory muscles in patients with COPD.